Xuelei Zhang1,2,3,4, Gang Luo1,2,3,4, Baixue Jia1,2,3,4, Dapeng Mo1,2,3,4, Ning Ma1,2,3,4, Feng Gao1,2,3,4, Jingyu Zhang1,2,3,4, Zhongrong Miao1,2,3,4. 1. 1 Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 2. 2 Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China. 3. 3 China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing, China. 4. 4 Beijing Institute for Brain Disorders, Beijing, China.
Abstract
BACKGROUND: Therapeutic strategies and outcomes vary with stroke subtypes for patients with acute vertebrobasilar occlusion (VBAO). This study aimed to compare characteristics and outcomes of VBAO due to intracranial atherosclerotic disease (ICAD) and embolisms and identify baseline predictors of ICAD. METHODS: Patients with VBAO who received endovascular therapy (EVT) were retrospectively analyzed. Participants fulfilling the criteria were classified as the ICAD group (focal stenosis of >70%, or fixed stenosis >50% in addition to either flow and perfusion impairment on angiography or an evident reocclusion tendency) and the embolism group (defined as no evidence of focal significant stenosis after thrombolysis or thrombectomy). Baseline characteristics and outcomes after EVT were compared between the two groups, and logistic regression was performed to explore the factors associated with ICAD. RESULTS: Among the 133 patients enrolled, 95 (71.4%) patients were categorized in the ICAD group, and 38 (28.6%) in the embolism group. A history of atrial fibrillation (odds ratio (OR) 0.142; 95% confidence interval (CI) (0.028-0.707), p = 0.017), distal basilar artery occlusion (OR 0.107; 95% CI (0.040-0.289), p < 0.001) and V4 segment occlusion (OR 3.423; 95% CI (1.172-9.999), p = 0.024) were independently associated with ICAD. Patients with VBAO due to ICAD had a lower rate of recanalization (81.1% vs 100%, p = 0.004), but the 90-day good clinical outcome was comparable (41.1% vs 50.0%, p = 0.347). CONCLUSIONS: The occlusion sites and a history of atrial fibrillation might be helpful in predicting ICAD in patients with VBAO. Patients with ICAD who were treated by EVT had a lower rate of recanalization but comparable 90-day good outcomes.
BACKGROUND: Therapeutic strategies and outcomes vary with stroke subtypes for patients with acute vertebrobasilar occlusion (VBAO). This study aimed to compare characteristics and outcomes of VBAO due to intracranial atherosclerotic disease (ICAD) and embolisms and identify baseline predictors of ICAD. METHODS:Patients with VBAO who received endovascular therapy (EVT) were retrospectively analyzed. Participants fulfilling the criteria were classified as the ICAD group (focal stenosis of >70%, or fixed stenosis >50% in addition to either flow and perfusion impairment on angiography or an evident reocclusion tendency) and the embolism group (defined as no evidence of focal significant stenosis after thrombolysis or thrombectomy). Baseline characteristics and outcomes after EVT were compared between the two groups, and logistic regression was performed to explore the factors associated with ICAD. RESULTS: Among the 133 patients enrolled, 95 (71.4%) patients were categorized in the ICAD group, and 38 (28.6%) in the embolism group. A history of atrial fibrillation (odds ratio (OR) 0.142; 95% confidence interval (CI) (0.028-0.707), p = 0.017), distal basilar artery occlusion (OR 0.107; 95% CI (0.040-0.289), p < 0.001) and V4 segment occlusion (OR 3.423; 95% CI (1.172-9.999), p = 0.024) were independently associated with ICAD. Patients with VBAO due to ICAD had a lower rate of recanalization (81.1% vs 100%, p = 0.004), but the 90-day good clinical outcome was comparable (41.1% vs 50.0%, p = 0.347). CONCLUSIONS: The occlusion sites and a history of atrial fibrillation might be helpful in predicting ICAD in patients with VBAO. Patients with ICAD who were treated by EVT had a lower rate of recanalization but comparable 90-day good outcomes.
Authors: Jeffrey L Saver; Reza Jahan; Elad I Levy; Tudor G Jovin; Blaise Baxter; Raul G Nogueira; Wayne Clark; Ronald Budzik; Osama O Zaidat Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Jin Soo Lee; Ji Man Hong; Kyu Sun Lee; Hong Il Suh; Andrew M Demchuk; Yang-Ha Hwang; Byung Moon Kim; Jong S Kim Journal: J Stroke Cerebrovasc Dis Date: 2015-07-09 Impact factor: 2.136
Authors: Simon D Israeli-korn; Yvonne Schwammenthal; Tali Yonash-Kimchi; Mati Bakon; Rakefet Tsabari; David Orion; Bella Bruk; Noa Molshatzki; Oleg Merzeliak; Joab Chapman; David Tanne Journal: Isr Med Assoc J Date: 2010-11 Impact factor: 0.892
Authors: Wouter J Schonewille; Christine A C Wijman; Patrik Michel; Christina M Rueckert; Christian Weimar; Heinrich P Mattle; Stefan T Engelter; David Tanne; Keith W Muir; Carlos A Molina; Vincent Thijs; Heinrich Audebert; Thomas Pfefferkorn; Kristina Szabo; Perttu J Lindsberg; Gabriel de Freitas; L Jaap Kappelle; Ale Algra Journal: Lancet Neurol Date: 2009-07-03 Impact factor: 44.182
Authors: Volker Puetz; P N Sylaja; Shelagh B Coutts; Michael D Hill; Imanuel Dzialowski; Pia Mueller; Ulf Becker; Gabriele Urban; Christine O'Reilly; Philip A Barber; Pranshu Sharma; Mayank Goyal; Georg Gahn; Ruediger von Kummer; Andrew M Demchuk Journal: Stroke Date: 2008-07-10 Impact factor: 7.914
Authors: Andrea M Alexandre; Iacopo Valente; Arturo Consoli; Pietro Trombatore; Luca Scarcia; Mariangela Piano; Nicola Limbucci; Joseph Domenico Gabrieli; Riccardo Russo; Antonio Armando Caragliano; Maria Ruggiero; Andrea Saletti; Guido Andrea Lazzarotti; Marco Pileggi; Mirco Cosottini; Fabio Pilato; Artur Slomka; Francesca Colò; Francesca Giubbolini; Giovanni Frisullo; Giacomo Della Marca; Aldobrando Broccolini; Alessandro Pedicelli Journal: Life (Basel) Date: 2021-12-17